Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12781
Title: Programmed cell death-1 inhibition in lymphoma.
Austin Authors: Hawkes, Eliza A ;Grigg, Andrew P ;Chong, Geoffrey 
Affiliation: Monash University, Melbourne, VIC, Australia
Department of Medical Oncology, Ballarat Health Services, Ballarat, VIC, Australia
University of Melbourne, Melbourne, VIC, Australia
Department of Oncology, Northern Hospital, Melbourne, VIC, Australia
Department of Medical Oncology, Eastern Health, Melbourne, VIC Australia
Department of Medical Oncology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia
Department of Clinical Haematology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia
Issue Date: 1-May-2015
Publication information: The Lancet. Oncology; 16(5): e234-45
Abstract: Cancers can evade the host immune system by inducing upregulation of immune inhibitory signals. Anti-programmed cell death-1 (PD-1) monoclonal antibodies block these inhibitory signals allowing the host to mount an immune response against malignant cells. This class of drugs is active in solid tumours, where upregulation of cell-surface PD-1 ligand proteins is nearly uniform. Because lymphoma is a malignancy of immune system cells, the role of the PD-1 pathway in these neoplasms is more complex. However, early clinical trials using PD-1 inhibitors have shown significant clinical activity in various subtypes of relapsed lymphoma. In this Review, we assess the scientific literature on the role of the PD-1 pathway in lymphoma, the relevant clinical data for PD-1 inhibition, and future strategies for this next generation of anticancer agents.
Gov't Doc #: 25943068
URI: http://ahro.austin.org.au/austinjspui/handle/1/12781
DOI: 10.1016/S1470-2045(15)70103-8
URL: https://pubmed.ncbi.nlm.nih.gov/25943068
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

10
checked on Dec 9, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.